Ki-67 and Tumor Size in Small Bowel Tumors: Findings from an Exploratory Immunohistochemical Analysis
Authors:
- Laurențiu Augustus BarbuLBLaurențiu Augustus Barbu
- Liliana CercelaruLCLiliana Cercelaru
- Valeriu ȘurlinVȘValeriu Șurlin
- Stelian-Stefaniță MogoantăSMStelian-Stefaniță Mogoantă
- Tiberiu Stefăniță Țenea CojanTCTiberiu Stefăniță Țenea Cojan
- Daniela MarinescuDMDaniela Marinescu
- Nicolae-Dragoș MărgăritescuNMNicolae-Dragoș Mărgăritescu
- Liviu VasileLVLiviu Vasile
Open Access
Abstract
Background: Small bowel tumors are rare and biologically diverse, and prognostic assessment remains difficult, particularly regarding proliferative markers such as Ki-67 and tumor size. Objective: To evaluate the clinicopathological and immunohistochemical characteristics of small bowel tumors and explore factors associated with malignancy. Methods: A retrospective analysis of 61 surgically treated primary small bowel tumors (2020–2024) was performed using WHO 2019/2022 and AJCC 8th criteria. Immunohistochemistry included CD117, DOG1, CD34, SMA, and Ki-67. Results: Adenocarcinomas were most frequent (52.5%), followed by GISTs (26.2%) and NETs (9.8%). CD117 and DOG1 were expressed in 93.8% of GISTs, confirming high diagnostic specificity. The median Ki-67 index was 8%, significantly higher in non-GIST tumors (p = 0.004). Tumor size correlated moderately with Ki-67 (ρ = 0.42, p = 0.018). In this exploratory model, tumor size > 5 cm (p = 0.03) and Ki-67 > 10% (p = 0.04) were associated with malignancy. Conclusions: Tumor size and Ki-67 were associated with malignancy in this exploratory multivariable analysis, but these findings should be interpreted with caution due to limited follow-up and sample imbalance. Combined with CD117/DOG1 profiling, they enhance diagnostic accuracy and may inform diagnostic assessment; however, prognostic implications require outcome-based studies.Keywords
Funding Information
- University of Medicine and Pharmacy of Craiova, Romania
This publication has 34 references indexed in Scilit:
- Unraveling the site-specific features in small intestinal stromal tumors: a retrospective studyBMC Gastroenterology, 2025
- An update on gastrointestinal stromal tumors (GISTs) with a focus on extragastrointestinal stromal tumors (EGISTs)Gastroenterology Report, 2025
- Prediction of Ki-67 expression and malignant potential in gastrointestinal stromal tumors: novel models based on CE-CT and serological indicatorsBMC Cancer, 2024
- Current Perspectives on Small Bowel Tumors: Overview of Prevalence, Clinical Manifestations, and Treatment ApproachesSiriraj Medical Journal, 2024
- Epidemiology, Risk Factors and Diagnosis of Small Bowel AdenocarcinomaCancers, 2022
- Molecular Landscape of Small Bowel AdenocarcinomaCancers, 2022
- Postoperative morbidity and mortality after surgical resection of small bowel neuroendocrine neoplasms: A systematic review and meta‐analysisJournal of Neuroendocrinology, 2021
- Clinical Features, Management, and Molecular Characteristics of Familial Small Bowel Neuroendocrine TumorsFrontiers in Endocrinology, 2021
- Recent advances in the management of gastrointestinal stromal tumorWorld Journal of Clinical Cases, 2020
- Gastrointestinal stromal tumors (GISTs): CD117, DOG-1 and PKCθ expression. Is there any advantage in using several markers?Pathology - Research and Practice, 2011